Key facts
- This page summarizes Eric Dobmeier's Form 4/A filing for Janux Therapeutics, Inc. (JANX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Jul 2024, 20:00.
Eric Dobmeier - 19 Jul 2024 Form 4/A Insider Report for Janux Therapeutics, Inc. (JANX)
- Reporting relationship
- Director
- Issuer ticker
- JANX
- Reported as of
- 19 Jul 2024
- Net transaction value
- $0
- SEC form
- 4/A
- Accepted by SEC
- 24 Jul 2024, 20:00:08 UTC
- Original report date
- 22 Jul 2024
- Prior SEC filing
- 27 Jun 2024
- Next SEC filing
- 01 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Pennington, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Eric Dobmeier filed Form 4/A for Janux Therapeutics, Inc. (JANX) on 24 Jul 2024.
Change
- Previous filing in this sequence was filed on 27 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
JANX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,231
- Change %
- +25%
- Price
- $0.000000
- Shares after
- 6,231
- Date
- 19 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
JANX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +4,111
- Change %
- Price
- $0.000000
- Shares after
- 4,111
- Date
- 19 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,111
- Exercise price
- $44.68
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the grant of RSUs, each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on July 19, 2025, subject to the Reporting Person's continuous service on such date.
Footnote F2
The shares subject to the option will vest in twelve equal monthly installments over one year, subject to the Reporting Person's continuous service on each such date.
SEC remarks
This amendment is being filed to correct the number of RSUs and the number of shares subject to the option.